- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Seralutinib, Gereic Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- Gossamer Bio USA, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 33
- States / cities
- Fresno, California • Los Angeles, California • Sacramento, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- GB002 (seralutinib), Generic Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- Gossamer Bio USA, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 15
- States / cities
- Sacramento, California • Santa Barbara, California • Jacksonville, Florida + 11 more
- Conditions
- Pulmonary Hypertension Associated With Interstitial Lung Disease
- Interventions
- Placebo, Seralutinib, Generic Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- GB002, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Fresno, California • Albuquerque, New Mexico • Richmond, Virginia
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Placebo, Seralutinib, Generic Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- GB002, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Fresno, California • Los Angeles, California + 40 more
- Conditions
- Pulmonary Artery Hypertension
- Interventions
- GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more